Flerie AB FLERIE

OMXSTO · Sweden · Health Technology

SEK 16.10-0.20 (-1.23%)

Market closed· Oct 1, 2026, 3:29 PM UTC· SEK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Flerie AB FLERIE

OMXSTO · Sweden · Health Technology

SEK 16.10-0.20 (-1.23%)

Market closed· Oct 1, 2026, 3:29 PM UTC· SEK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-39.67% · 6MFull-screen chart

Open SEK 16.30High SEK 16.30Low SEK 15.70Close SEK 16.10Volume 59.87K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: SEK 16.30
Day range: SEK 15.70 – SEK 16.30
52-week range: SEK 15.70 – SEK 37.41
Volume: 59.87K
Market cap: SEK 1.48B
Next earnings date: 2026-10-15
Avg. volume (1Y): 32.62K

Performance

1 week

-7.47%

1 month

-5.57%

3 months

-21.08%

6 months

-37.63%

Year to date

-50.60%

1 year

-56.45%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Sweden
Exchange: OMXSTO
Shares outstanding: 86.70M
Employees: 10
ISIN: SE0022447348
Beta: -0.17

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceSep 30, 2026

AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness

Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB and new investor Innovestor Life ScienceProceeds will fund Phase 2b development of AC01, a first-in-class oral therapy designed to improve cardiac contractility and outcomes in patients with advanced heart failurePhase 1b/2a GOAL-HF1 study demonstrated clinical proof of concept,

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.